

Index

- A**
- ACC, 188
 - ADAM6, 31
 - AI. *See* Artificial intelligence
 - AKT, activation in cancer, 4
 - ALK
 - immune checkpoint inhibitor therapy
 - in non-small-cell lung cancer, 71–72
 - mouse models of lung cancer, 102, 107–108, 112
 - radiogenomics, 163
 - rearrangements in lung cancer, 24, 64
 - ARID1A, 202
 - Artificial intelligence (AI)
 - molecular pathology data interpretation, 41–42
 - radiomics
 - lung cancer applications
 - early detection and screening, 153–156
 - prognosis, 156–159
 - radiogenomics, 160, 163–164
 - treatment response, 157, 160–162
 - overview, 150–153
 - ASCL1, 172, 221–222
 - ASNS. *See* Asparagine synthase
 - Asparagine synthase (ASNS), 187
 - AZD3965, 187
- B**
- BAP1, 35
 - BCL9, 139
 - BEAS-2B, preclinical studies of lung cancer
 - pathogenesis, 5–6
 - β -catenin, 138–139
 - BRAF
 - alterations in lung cancer, 25
 - mutations in early lung cancer, 2
 - BRD4, 203, 206
 - BRG1, 139, 202
- C**
- CA125, 9
 - Cancer stem cell (CSC)
 - antitumor immunity, 140–141
 - clinical implications, 141–142
 - drug persistence and signaling, 138–139
 - heterogeneity, 137
 - hypothesis in lung cancer, 134–136
 - minimal residual disease role, 137–138
 - niche, 138–139
 - NOTCH signaling, 138
 - origins of lung cancer, 136–137
 - overview, 133–134
 - Shh signaling, 139
 - tumor heterogeneity role, 137–138
 - CBP, 204
 - CCAT1, 207
 - CD59, 5
 - CD200, 5
 - CDKN2A, 4
 - CEA, 9
 - Cell-free DNA (cfDNA)
 - fragmentation profile, 40
 - immune checkpoint inhibitor therapy response
 - biomarker, 75–76
 - methylation, 9
 - relapse/recurrence detection, 12
 - cfDNA. *See* Cell-free DNA
 - Chromatin remodeling. *See* Epigenetics
 - Circular RNA, therapeutic targeting, 208
 - Circulating tumor cells (CTCs)
 - characterization, 10
 - DNA. *See also* Cell-free DNA
 - analysis, 39–40
 - immune checkpoint inhibitor therapy
 - response biomarker, 75–76
 - isolation, 10
 - non-small-cell lung cancer detection
 - advanced cancer, 11
 - early cancer, 10–11
 - quantification, 39
 - relapse/recurrence detection, 9–12
 - small-cell lung cancer, 11–12
 - CKD7, 231
 - COL1A2, 31
 - COL3A1, 31
 - Computed tomography (CT). *See also* Radiomics
 - early-stage non-small-cell lung cancer, 86
 - locally advanced non-small-cell lung cancer, 89
 - lung cancer screening, 7–8
 - tumor metabolism imaging, 173–174
 - CREBBP, 221

Index

CSC. *See* Cancer stem cell
CT. *See* Computed tomography
CTCs. *See* Circulating tumor cells
CTLA-4
 immune checkpoint, 68–69
 immune checkpoint inhibitor therapy for non-small-cell lung cancer, 70–71, 73, 229
CYFRA 21-1, 9

D

DCCPS, 246
Deep learning (DL), molecular pathology data interpretation, 41–42
DL. *See* Deep learning
DNA methylation. *See* Epigenetics
DNMT1, 201
DNMT3a, 201
DNMT3b, 201
Durvalumab, 90

E

EGFR
 gene family mutations in lung cancer, 23–24, 71
 immune checkpoint inhibitor therapy
 in non-small-cell lung cancer, 71–72
 intertumor heterogeneity, 30, 35–37
 mouse models of lung cancer, 99, 107–108, 114, 118
 mutations in early lung cancer, 2
 radiogenomics, 163
EGFR
 metabolic changes in lung cancer
 alterations, 181–182
 therapeutic targeting, 183, 187
EML4, 24, 102
Epigenetics
 biomarkers in lung cancer, 209
 lung cancer studies, 27, 29
 targeting in lung cancer
 chromatin remodeling, 202
 circular RNA, 208
 DNA methylation, 201–202
 histone modifications
 acetylation, 204–205
 methylation, 203–204
 readers, 205–206
 long noncoding RNA, 207–208
 microRNA, 206–207, 209
 rationale, 199–201
 small nucleolar RNA, 208
ERBB2, 4, 24
EZH2, 204, 228

F

FADS2, 188
FHIT, 3
FOXO3, 208

G

Gene expression profiling (GEP), lung cancer studies, 26
Genetically engineered mice. *See* Mouse models
GENIE, 255
GEP. *See* Gene expression profiling
GLUT1, 172, 177
Gut microbiome, immune checkpoint inhibitor therapy response biomarker, 76–77

H

HBEC. *See* Human bronchial epithelium cell
HDAC. *See* Histone deacetylase
HDGF. *See* Hepatoma-derived growth factor
Hepatoma-derived growth factor (HDGF), 207
Histone deacetylase (HDAC)
 HDAC3, 205
 HDAC6, 206
 HDAC7, 204
 inhibitors, 29
Histone modifications. *See* Epigenetics
HLA-G, 5
HOTAIR, 207
HSAEC. *See* Human small airway epithelium cell
HTAN. *See* Human Tumor Atlas Network
Human bronchial epithelium cell (HBEC),
 preclinical studies of lung cancer
 pathogenesis, 6
Human small airway epithelium cell (HSAEC),
 preclinical studies of lung cancer
 pathogenesis, 6
Human Tumor Atlas Network (HTAN), 255

I

ICIs. *See* Immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs)
 protein targets. *See specific proteins*
 therapy for non-small-cell lung cancer
 advanced/unresectable disease, 72–73
 biomarkers of response
 circulating tumor DNA, 75–76
 gut microbiome, 76–77
 PDL-1, 74–75
 tumor mutational burden, 75
 checkpoint proteins, 68–69
 early-stage disease

- adjuvant immunotherapy, 73
 - neoadjuvant immunotherapy, 73–74
 - metastasis
 - actionable molecular aberrations, 71–72
 - first-line therapy, 70–71
 - second-line therapy, 71
 - overview, 64
 - resistance mechanisms, 64
 - IMPDH, 172
 - INTERCEPT study, 41
 - Intertumor heterogeneity
 - adenosquamous carcinoma, 33
 - atypical carcinoid, 33
 - biomarkers, 30–31
 - bronchial mucoepidermoid carcinoma, 34
 - clonality, 35–37
 - large-cell lung carcinoma, 33
 - lung adenocarcinoma, 32
 - non-small-cell lung cancer, 31–32
 - overview, 29–30
 - pulmonary sarcomatoid carcinoma, 33–34
 - small-cell lung cancer
 - clinical significance, 224
 - floaters and stickers, 222
 - neuroendocrine versus non-neuroendocrine cells, 222
 - NOTCH expression, 222–223
 - overview, 34
 - subclonal mutations, 223–224
 - tumor-propagating cells, 223
 - vasculogenic mimicry, 223
 - squamous cell carcinoma, 33
 - typical carcinoid, 33
- K**
- KDM3A, 203
 - KEAP1
 - metabolic changes in lung cancer alterations, 179–180
 - mouse models of lung cancer, 106
 - therapeutic targeting, 187
 - Knockout mice. *See* Mouse models
 - KRAS
 - alterations in lung cancer, 24–25
 - intertumor heterogeneity, 31
 - metabolic changes in lung cancer alterations, 178–179
 - mouse models of lung cancer, 99, 102, 105–106, 108, 117
 - mutations in early lung cancer, 2
 - radiogenomics, 163
- L**
- LAG-3, immune checkpoint, 69
 - LCE. *See* Lung Cancer Explorer
 - LKB1, 4, 117
 - LKB1
 - metabolic changes in lung cancer alterations, 180–181
 - therapeutic targeting, 183, 187
 - lncRNA. *See* Long noncoding RNA
 - LOH. *See* Loss of heterozygosity
 - Long noncoding RNA (lncRNA), therapeutic targeting, 207–208
 - Loss of heterozygosity (LOH), early carcinogenesis, 3
 - LSD1, 204
 - LUAD. *See* Lung adenocarcinoma
 - Lung adenocarcinoma (LUAD)
 - intertumor heterogeneity, 32
 - metabolomics, 172
 - mouse models, 99, 102
 - Lung Cancer Explorer (LCE), 255–259
 - Lung squamous cell carcinoma (LUSC)
 - intertumor heterogeneity, 33
 - metabolomics, 172
 - mouse models, 102–103
 - LUSC. *See* Lung squamous cell carcinoma
- M**
- Machine learning. *See* Artificial intelligence
 - Magnetic resonance imaging (MRI). *See* Radiomics
 - MALAT1, 207
 - MCP-1, tumor microenvironment, 66
 - MCT1, 172, 187
 - MET, alterations in lung cancer, 25
 - Metabolomics
 - cross talk in tumor microenvironment, 182–183
 - imaging tumor metabolism
 - computed tomography, 173–174
 - metabolic processes, 175
 - overview, 172–173
 - positron emission tomography
 - amino acid tracers, 176
 - glucose tracers, 174, 176
 - mitochondrial function, 176–177
 - nucleotide metabolism, 176
 - oxygen metabolism, 176
 - principles, 174
 - in situ tumor studies, 172–173
 - lung cancer histology studies, 172
 - molecular alterations and metabolic changes
 - EGFR, 181–182
 - KEAP1, 179–180
 - KRAS, 178–179
 - LKB1, 180–181

Index

- Metabolomics (*Continued*)
MYC, 182
NRD2, 179–180
overview, 177
p53, 177–178
PI3K, 179
therapeutic targeting of metabolism
 amino acid metabolism, 187
 glucose metabolism, 183, 187
 lipid metabolism, 188
 mitochondrial metabolism, 187–188
 overview, 183–186
- Metastasis, non-small-cell lung cancer
 adoptive cell therapy with tumor-infiltrating lymphocytes, 69–70
 immune checkpoint inhibitor therapy
 actionable molecular aberrations, 71–72
 first-line therapy, 70–71
 second-line therapy, 71
 mouse models, 105
 radiation therapy, 90–92
- MicroRNA
 lung cancer studies, 27–28
 therapeutic targeting, 206–207, 209
- Minimal residual disease (MRD)
 cancer stem cell role, 137–138
 ctDNA as biomarker, 75–76
 detection, 12
- Mouse models
 cancer immunology studies, 107–108
 cell of origin studies, 104–105
 genetically engineered mice prospects, 105–107
 lung adenocarcinoma, 99, 102
 lung squamous cell carcinoma, 102–103
 metastasis, 105
 overview of lung cancer models, 98–99
 rationale, 97–98
 resources, 258, 260, 263
 small-cell lung cancer, 103
 therapy studies for lung cancer
 challenges with clinical translation, 118–119
 drug resistance, 117–118
 drug target discovery, 117
 efficacy, 114, 117
 mechanism of action, 114, 117
 timeline of development for lung cancer, 100–102
 tumor initiation and progression, 103–104
 tumor progression, 105
 xenograft studies
 cell lines, 109–110
 humanized mice, 113–114
 lung differentiation and tumor pathogenesis studies, 114
 overview, 108–109
 patient-derived xenografts, 111–113
 small-cell lung cancer, 219–220
 three-dimensional cultures and organoids, 109, 111
- MRD. *See* Minimal residual disease
MRI. *See* Magnetic resonance imaging
MYC, 221
MYC, metabolic changes in lung cancer alterations, 182
MYCL, 221
- N**
- National Comprehensive Cancer Network (NCCN), guidelines, 40–41, 250
National Lung Screening Trial (NLST), 7–8, 152–153, 156, 252
NCCN. *See* National Comprehensive Cancer Network
NCDB, 246
NELSON, 8
NEUROD1, 221–222
NF1, 106
NHBE cell. *See* Normal human bronchial epithelium cell
NKX2-1, 4, 104
NLST. *See* National Lung Screening Trial
Nomogram, lung cancer tools, 250–251
Non-small-cell lung cancer (NSCLC)
 adoptive cell therapy with tumor-infiltrating lymphocytes for metastasis, 69–70
 circulating tumor cells in detection
 advanced cancer, 11
 early cancer, 10–11
 immune checkpoint inhibitor therapy
 advanced/unresectable disease, 72–73
 biomarkers of response
 circulating tumor DNA, 75–76
 gut microbiome, 76–77
 PDL-1, 74–75
 tumor mutational burden, 75
 checkpoint proteins, 68–69
 early-stage disease
 adjuvant immunotherapy, 73
 neoadjuvant immunotherapy, 73–74
 metastasis
 actionable molecular aberrations, 71–72
 first-line therapy, 70–71
 second-line therapy, 71
 overview, 64
 resistance mechanisms, 64
 immune microenvironment, 64–67

- Non-small-cell lung cancer (NSCLC) (*Continued*)
 immunoediting and immunosuppression
 mechanisms, 67–68
 intertumor heterogeneity, 31–32
 metabolomics, 172
 radiation therapy
 early-stage cancer, 85–89
 locally advanced cancer
 resectable, 89
 unresectable, 89–90
 stage IV and metastasis, 90–92
- Normal human bronchial epithelium (NHBE) cell,
 preclinical studies of lung cancer
 pathogenesis, 5
- NOTCH, 138, 222–224
- NOTCH3, 138–139
- NRD2, metabolic changes in lung cancer alterations,
 179–180
- NSCLC. *See* Non-small-cell lung cancer
- NSF1, 109
- NTRK, fusions in lung cancer, 25–26
- P**
- p16^{INK4A}, alterations in early lung cancer, 4
- p53
 gene. *See* TP53
 metabolic changes in lung cancer alterations,
 177–178
- p300, 139
- PARP, small-cell lung cancer treatment with
 inhibitors, 226–227
- Patient-derived organotypic tumor spheroids
 (PDOTS), 111
- PD-1, 229
- PD-L1
 circulating tumor cell expression, 11
 expression and immunotherapy response, 37–38,
 64, 74–75
 immune checkpoint, 68
 immune checkpoint inhibitor therapy for non-
 small-cell lung cancer, 70
 immunosuppressive phenotype and
 immunotherapy, 230–232
 VEGFR correlation, 24
- PDOTS. *See* Patient-derived organotypic tumor
 spheroids
- PET. *See* Positron emission tomography
- PI3K, metabolic changes in lung cancer alterations, 179
- PI3K/AKT/PTEN/mTOR pathway, up-regulation in
 lung cancer, 26
- Positron emission tomography (PET). *See also*
 Radiomics
 early-stage non-small-cell lung cancer, 86
 locally advanced non-small-cell lung cancer, 89
 tumor immunoresistance studies, 68
 tumor metabolism imaging
 amino acid tracers, 176
 glucose tracers, 174, 176
 mitochondrial function, 176–177
 nucleotide metabolism, 176
 oxygen metabolism, 176
 principles, 174
- POUF23, 221–222
- Preclinical models. *See* Mouse models;
 specific cell lines
 cell line resources, 258, 260
 prospects for analysis and caveats, 260–263
- PRMT, 203
- Pro-SFTPB, 9
- PTEN, 220–221
- PTEN, 207
- R**
- Radiation therapy. *See* Non-small-cell lung cancer
- Radiomics
 artificial intelligence, 151–153
 limitations, 163, 165
 lung cancer early detection and screening,
 153–156
 overview, 147–148
 pipeline, 148–151
 prognosis of lung cancer, 156–159
 prospects, 165
 radiogenomics, 160, 163–164
 treatment response of lung cancer, 157, 160–162
- RBI, 3, 103, 114, 222
- RBL2, 220–221
- Recurrence. *See* Screening, lung cancer
- Registries, lung cancer, 246
- Relapse
 screening. *See* Screening, lung cancer
 small-cell lung cancer chemoresistance, 228–229
- RET, rearrangements in lung cancer, 25
- ROS1
 mouse models of lung cancer, 102, 112
 rearrangements in lung cancer, 25
- RTKN2, 31
- Runx, 104
- S**
- SAHA, 206
- SCD, 188
- SCLC. *See* Small-cell lung cancer
- Screening, lung cancer
 AKT activation, 4

Index

- Screening, lung cancer (*Continued*)
 atypical adenomatous hyperplasia
 abnormalities, 4–6
 biological rationale, 6–7
 chromosomal abnormalities, 3–4
 molecular abnormalities in preneoplasia, 1–3
 radiomics, 153–156
 relapse/recurrence detection
 cell-free DNA, 12
 circulating tumor cells, 9–12
 sputum and blood markers, 9
 successes and challenges, 7–9
SEER, 246, 250
SGLT2, therapeutic targeting, 187
Shh, lung cancer stem cell signaling, 139
SLC1A5, 172
SLC7A11, 187
SLFN11, small-cell lung cancer chemoresistance
 role, 227–228
Small nucleolar RNA (snoRNA), therapeutic
 targeting, 208
Small-cell lung cancer (SCLC)
 cell lines, 218–219, 222
 chemoresistance
 EZH2 role, 228
 PARP inhibitors, 226–227
 relapse, 228–229
 SLFN11 role, 227–228
 circulating tumor cells, 11–12
 genomics and oncogenes, 220–222
 immunosuppressive phenotype and
 immunotherapy, 229–231
 intertumor heterogeneity, 34
 intratumoral heterogeneity
 clinical significance, 224
 floaters and stickers, 222
 neuroendocrine versus non-neuroendocrine
 cells, 222
 NOTCH expression, 222–223
 subclonal mutations, 223–224
 tumor-propagating cells, 223
 vasculogenic mimicry, 223
 lineage plasticity and transdifferentiation,
 225–226
 metabolomics, 172
 models, 218–220
 mouse models, 103
 origins, 224–225
 overview, 217
SMARCA3, 203
SMARCA4, 202–203
snoRNA. *See* Small nucleolar RNA
SOX2
 alterations in early lung cancer, 3
 mouse models of lung cancer, 103
SPINK1, 31
Squamous cell carcinoma. *See* Lung squamous
 cell carcinoma
STK11, 64
STK11. *See* LKB1
- T**
TAK-288, 187
TAM. *See* Tumor-associated macrophage
TCGA. *See* The Cancer Genome Atlas
TCIA. *See* The Cancer Imaging Archive
Tertiary lymphoid structure (TLS), tumor
 microenvironment, 66–67
TGFB1, 4
TGFB3, 5
The Cancer Genome Atlas (TCGA), 29, 32–34,
 252–253, 255, 257
The Cancer Imaging Archive (TCIA), 152, 252
TIL. *See* Tumor-infiltrating lymphocyte
TIM-3, immune checkpoint, 69
TLS. *See* Tertiary lymphoid structure
TMB. *See* Tumor mutational burden
TNFRS14, 5
TP53
 intertumor heterogeneity, 30
 mouse models of lung cancer, 103, 105, 114, 117
 mutations in early lung cancer, 2–3
 small-cell lung cancer mutations, 222
Transgenic mice. *See* Mouse models
Tumor-infiltrating lymphocyte (TIL), adoptive cell
 therapy for non-small-cell lung cancer
 metastasis, 69–70
Tumor mutational burden (TMB)
 causes of increase, 38
 immune checkpoint inhibitor therapy response
 biomarker, 75
 immunogenic response, 38–39
 PD-L1 expression and immunotherapy response,
 37–38
Tumor-associated macrophage (TAM), 66
- V**
VEGF, tumor microenvironment, 66
VEGFR, 24
- X**
Xenograft. *See* Mouse models
- Y**
YEATS2, 206